Among them, dupilumab was clinically approved for AD (Figure 3); dupilumab blocks interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by binding to interleukin 4 receptor (IL4R). Here, IL13 is linked to Alzheimer disease.